IL17A and respiratory tract infectious disorder: However, IL-17 inhibitors have been reported to increase the risk of respiratory infections (15–17), so it needs to be considered whether psoriasis patients treated with IL-17 inhibitors are more susceptible to the virus during the COVID-19 pandemic.